Welcome to our dedicated page for Pacific Biosc SEC filings (Ticker: PACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
ARK Investment Management LLC and Catherine D. Wood report significant ownership in Pacific Biosciences of California, Inc. They disclose beneficial ownership of 37,264,228 shares of the company’s common stock, representing 12.34% of the class, based on an event date of December 31, 2025. ARK has sole voting power over 34,971,286 shares and shared voting power over 620,864 shares, while Wood has shared voting power over 35,592,150 shares. Both certify the holdings were acquired and are held in the ordinary course of business, not for changing or influencing control. ARK Innovation ETF is noted as a client with an interest exceeding 5%.
Pacific Biosciences of California, Inc. completed an asset sale to Illumina Cambridge Limited, transferring intellectual property and other assets tied to its short-read DNA sequencing and related reagent and detection technologies. The buyer paid $50.0 million in cash and assumed certain liabilities.
PacBio also received a non-exclusive license back to some of the sold intellectual property, allowing continued access to those technologies. At PacBio’s direction, the buyer will pay 4% of the net proceeds from the purchase price to former Apton Biosystems equity holders in connection with waived milestones, leaving PacBio with approximately $48.1 million in net cash proceeds from the transaction.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.
Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.
Pacific Biosciences (PACB) filed its quarterly report, highlighting restructuring impacts and continued losses. Q3 revenue was $38.4 million versus $40.0 million a year ago, while gross profit improved to $15.9 million. Operating loss narrowed to $38.9 million from $64.1 million as cost of revenue declined.
Year to date, the company recorded a net loss of $506.0 million, driven primarily by $359.3 million of accelerated amortization tied to discontinued short-read development and a $15.0 million IPR&D impairment. Stockholders’ equity fell to $36.1 million from $506.6 million at year-end. Cash and investments totaled $298.7 million as of September 30, including $56.5 million in cash. Operating cash outflow was $92.1 million for the nine months. Convertible notes totaled $645.2 million (net), including the 2029 and 2030 notes; contingent consideration from the Apton deal was reduced to $0. Shares outstanding were 301,907,431 as of October 31, 2025.
Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”
The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.
Pacific Biosciences of California, Inc. reported that it announced financial results for its third fiscal quarter ended September 30, 2025. The company disclosed that these third-quarter 2025 results, covering its results of operations and financial condition, are presented in a press release titled “PacBio Announces Third Quarter 2025 Financial Results.”
The press release is furnished as Exhibit 99.1 to this report, meaning it provides the detailed quarterly figures and commentary, while the report itself primarily serves to formally notify investors that the results have been released.
Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), reported a routine sale of shares to cover tax withholding upon RSU vesting. The Form 4 discloses that on 08/18/2025 he disposed of 26,836 shares at a weighted average sale price of $1.311 per share (sale prices ranged from $1.30 to $1.32). After the transaction he beneficially owns 1,920,035 shares. The filing explains the shares were automatically sold to satisfy tax withholding obligations related to restricted stock unit vesting. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Pacific Biosciences (PACB) filed a Form 144 reporting a proposed sale of 26,836 restricted common shares acquired on 08/15/2025. The filing lists the broker as Morgan Stanley Smith Barney LLC and shows an aggregate market value of $35,173.95 with an approximate sale date of 08/18/2025 on NASDAQ. The issuer's total shares outstanding are reported as 300,370,611. The filer indicates there were no securities sold in the past three months for the same account and signs the standard representation that they are not aware of undisclosed material adverse information.
Multiple related parties reported material holdings in Pacific Biosciences (PACB). Madrone Opportunity Fund directly holds 16,762,216 shares (5.6% of class) and Shimoda Holdings directly holds 3,500,000 shares (1.2%). Gregory Boyd Penner is reported as an individual with aggregate beneficial ownership of 20,262,216 shares (6.8% of class), reflecting his roles across the filing entities.
The filing discloses that the reported shares carry shared voting and shared dispositive power among the reporting persons and that the percentage figures are calculated using 300,084,685 shares outstanding as the denominator. The reporting persons expressly disclaim status as a "group."